The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...

Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report report ...

Fintel reports that on March 21, 2025, Citizens Capital Markets downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from Market Outperform to Market Perform. Analyst Price Forecast ...

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

Acelyrin was explicit that it had made the changes in response to the “continued rapid accumulation” of 8.8% of the biotech’s stock by Tang Capital Partners. Acelyrin had already turned down ...

Presently, Tang, via his hedge fund Tang Capital Partners and his privately held shell company, Concentra Biosciences, has a $3-per-share cash offer on the table to acquire and shut down ...

LOS ANGELES - Acelyrin Inc. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology treatments, has implemented a stockholder rights plan following Tang Capital Partners ...

LOS ANGELES - Acelyrin Inc. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology treatments, has implemented a stockholder rights plan following Tang Capital Partners’ acquisition of ...

Los Angeles-based Acelyrin consulted with independent financial and legal advisors and came to the conclusion that the unsolicited interest from Tang Capital Partners-owned Concentra was “not ...